Stockwinners Market Radar for July 23, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment buys 122K shares of 10x Genomics today

19:03 EDT NuZee 10% holder buys $797.5K in common stock - In a regulatory filing, NuZee disclosed that its 10% holder Yumei Liu bought 524.5K shares of common stock on July 18th in a total transaction size of $797.5K. Shares of NuZee are up 86% afterhours at $1.92.

18:29 EDT Tesla CEO says end of IRA if Trump wins would be 'devastating to competitors' - Says value of Tesla "overwhelmingly is autonomy". Says if you believe Tesla will solve autonomy, you should buy Tesla stock.

17:57 EDT Seagate expects mass capacity sales to trend higher in September quarter - "Pleased" with trend in gross margin improvement. Says "very positive" on gross margin for current quarter. Says in early innings of Gen AI.

17:48 EDT Tesla says first Robotaxi ride timing depends on unsupervised driving progress - Says first Robotaxi ride depends on the timing of first unsupervised driving, which is likely some time this year. Says would be "shocked" if unsupervized driving had to wait until next year.

17:44 EDT Tesla CEO Musk confirms delay of Robotaxi to October 10th - Says Tesla will unveil its lower-price model in first half of 2025. Comments taken from Q2 earnings conference call.

17:25 EDT Mattel says it will not comment on 'recent press reports and speculation' - Says confident in abilities as standalone company.

17:23 EDT Mattel sees growing sales, earnings in 2025

17:20 EDT FTC issues orders to 8 companies seeking information on 'surveillance pricing' - The Federal Trade Commission issued orders to eight companies offering surveillance pricing products and services that incorporate data about consumers' characteristics and behavior. The orders seek information about the potential impact these practices have on privacy, competition, and consumer protection. The orders are aimed at helping the FTC better understand the opaque market for products by third-party intermediaries that claim to use advanced algorithms, artificial intelligence and other technologies, along with personal information about consumers-such as their location, demographics, credit history, and browsing or shopping history-to categorize individuals and set a targeted price for a product or service. The study is aimed at helping the FTC better understand how surveillance pricing is affecting consumers, especially when the pricing is based on surveillance of an individual's personal characteristics and behavior. "Firms that harvest Americans' personal data can put people's privacy at risk. Now firms could be exploiting this vast trove of personal information to charge people higher prices," said FTC Chair Lina M. Khan. "Americans deserve to know whether businesses are using detailed consumer data to deploy surveillance pricing, and the FTC's inquiry will shed light on this shadowy ecosystem of pricing middlemen." The FTC is using its 6(b) authority, which authorizes the Commission to conduct wide-ranging studies that do not have a specific law enforcement purpose, to obtain information from eight firms that advertise their use of AI and other technologies along with historical and real-time customer information to target prices for individual consumers. The orders were sent to: Mastercard (MA), Revionics, Bloomreach, JPMorgan Chase (JPM), Task Software, PROS, Accenture (ACN), and McKinsey & Co.... Reference Link

17:17 EDT Avantor to replace QuidelOrtho in S&P 400 at open 7/26

17:11 EDT Mattel says toy industry outperformed in 1H24 - Says prioritizing growth in profitability and gross margin expansion this year. Says expects to benefit from innovation across toy portfolio. Says toy industry outperformed in the first half of the year and sees trends further improving in the second half of the year. Sees toy business growing in 2H24, says looking forward to a "good" holiday season. Comments taken from Q2 earnings conference call.

17:08 EDT Atkore announces CFO and CAO Transition - Atkore announced that David Johnson has submitted his resignation as VP, CFO and Chief Accounting Officer - CAO -, effective close of business on August 9, to pursue a career opportunity outside of the electrical industry. The company has appointed John Deitzer as its VP and CFO and James Alvey as its CAO upon Johnson's departure. Deitzer has more than 19 years' experience in investor relations, treasury, and corporate strategy. Most recently at Atkore, Deitzer was VP of Finance - Electrical business unit. He joined the company in 2019, serving as VP of Investor Relations and then adding oversight of ESG initiatives as well as the Treasury responsibilities. Prior to that, Deitzer spent four years at Alcoa Corporation in Investor Relations and Management Consulting & Strategy roles. Deitzer started his management career at PPG Industries. Alvey has been with the company for four years, most recently as Corporate Controller. Alvey will continue overseeing corporate accounting and external reporting, internal controls and policies. Prior to joining the company, Alvey spent more than 10 years at Ernst & Young as Audit Senior Manager.

17:02 EDT Alphabet says still expects quarterly capital expenditures at or above $12B - Says AI overview in Lens leads to increase of visual search. Says views on YouTube CTV increased more than 130% over past three years. Says monetization rates for Shorts showing healthy growth. Says last year viewers watched 30B hours of shopping related videos. Says shopping remains key area of investment. Says Q2 performance driven by search and cloud. Says pleased with YouTube growth. Says significant growth in subscriptions business. Says anniversaried price increase for YouTube TV in Q2. Says cloud continued to deliver strong results. Says particularly encouraged that majority of top 100 customers are already using AI solutions. Says headcount declined quarter-on-quarter. Says expects slight increase in headcount in Q3. Says still expects to deliver FY24 operating margin expansion relative to 2023. Says still expects quarterly capital expenditures at or above $12B. Says has chosen to commit to multiyear investment of $5B for Waymo. Comments and guidance taken from Q2 earnings conference call.

16:48 EDT Riot Platforms acquires Block Mining for $92.5M - Riot Platforms has acquired Block Mining, a Kentucky-based vertically integrated Bitcoin miner, for total consideration at closing of $92.5M. Riot paid the purchase price through $18.5M of cash from its balance sheet plus $74M of Riot common stock. Additional consideration, up to a maximum of $32.5M, can be earned by Block Mining through 2025 through the execution of additional power purchase agreements to add additional power capacity. The acquisition of Block Mining increases Riot's hash rate, expands Riot's footprint geographically, and provides exposure to additional energy markets outside of ERCOT. Block Mining is a vertically integrated Bitcoin miner consisting of two operational sites, both in Kentucky, totaling 60 MW of operational capacity with potential to expand up to 155 MW. Of the existing and operational 60 MW, 23 MW are currently being used for self-mining, 19 MW are vacant and available for immediate miner deployment, and 18 MW are contracted by Bitcoin mining tenants under hosting agreements. Riot intends to further expand Block Mining's two sites, targeting 110 MW for self-mining operations by the end of 2024. Additionally, Block Mining owns a greenfield expansion opportunity also in Kentucky, adjacent to an existing substation, presenting an opportunity to develop 60 MW and with potential to expand to 150 MW. Block Mining's sites are serviced by various power companies including the Tennessee Valley Authority.

16:42 EDT FS Bancorp raises dividend by 1c per share, expands share repurchase program - "I am pleased with our financial results for the second quarter, and I am excited about Matthew D. Mullet's recent well-deserved promotion to Bank President," stated Joe Adams, CEO. "Matthew will make a great president and we are both thankful to our Board of Directors for increasing our forty-sixth consecutive quarterly cash dividend by 1c to 27c per common share and expanding our share repurchase plan, demonstrating our continued commitment to enhancing shareholder value. The cash dividend will be paid on August 21 to shareholders of record as of August 7, 2024," concluded Adams

16:35 EDT EQT Corporation still sees 2024 total sales volume 2,100-2,200 Bcfe - Maintains 2024 EQT maintenance capital expenditures view $1.95B-$2.05B. The company also maintains its 2024 strategic growth capital expenditures guidance of $200M-$300M, which targets opportunistic, high-return water, midstream and other infrastructure and land opportunities. Following the close of the Equitrans acquisition, the company expects to spend $180M-$230M in the balance of 2024 for Equitrans capital expenditures.

16:32 EDT Kronos Bio:1st patient dosed in expansion cohort with KB-0742 for HGSOC - Kronos Bio announced the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule. This expansion cohort is enrolling platinum-resistant patients with high-grade serous ovarian cancer or HGSOC , a tumor type which is particularly sensitive to CDK9 inhibition due to MYC amplification or overexpression and deficiencies in homologous recombination or HRD+. ..."Pharmacokinetic modeling of 80mg four-days-on, three-days-off schedule shows a 1.8-fold increase in AUC over seven days relative to the 60mg three-days-on, four-days-off schedule. With this dose and schedule, we believe that KB-0742 will deliver therapeutic responses in this high unmet need population. We look forward to providing an update on the efficacy of KB-0742 in the first half of 2025." "We are excited for the focused expansion of KB-0742 in platinum-resistant HGSOC. KB-0742 has to date provided prolonged stable disease of over 300 days in one of my platinum-resistant HGSOC patients," said Howard "Skip" A. Burris M.D., president of Sarah Cannon Research Institute (SCRI). "HGSOC patients have limited treatment options after progressing on platinum therapy and KB-0742 brings new possibilities to those battling this devastating disease

16:31 EDT TechnipFMC awarded flexible pipe contract by Petrobras - TechnipFMC has been awarded a substantial contract by Petrobras to supply flexible pipe for the pre-salt fields offshore Brazil, following completion of a tender. The contract covers the design, engineering, and manufacture of flexible pipe for water injection and gas lift. For TechnipFMC, a "substantial" contract is between $250 million and $500 million. This award was included in inbound orders in the second quarter of 2024.

16:28 EDT Seagate provides debt capital structure - $2.9B Liquidity, $1.4B cash, $1.5B revolving credit facility. $5.7B debt, weighted average interest rate of 5.6%, weighted average maturity of ~5 years. Says more than 90% of company's long-term debt obligations are due in FY27 and beyond. Comments taken from investor presentation slides.

16:21 EDT Chubb reports Q2 P&C combined ratio 86.8% vs. 85.4% last year

16:20 EDT Paranovus Entertainment receives bid deficiency notice from Nasdaq - Paranovus Entertainment received a notification letter from Nasdaq notifying the company that the minimum bid price per share for its Class A ordinary shares has been below $1.00 for a period of 30 consecutive business days and the company therefore no longer meets the minimum bid price requirements. The notification received has no immediate effect on the listing of the Company's Class A ordinary shares on Nasdaq. The company has until January 13, 2025 to regain compliance. If the Company does not regain compliance during such 180-day period, the Company may be eligible for an additional 180 calendar days.

16:17 EDT Geron's Chief Commercial Officer Kapur to depart - Geron "announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to pursue other interests. A search for a new Chief Commercial Officer is already underway, and in the interim, Andrew Grethlein, Ph.D., Executive Vice President, Chief Operating Officer, will serve as leader of the commercial organization. Geron Board of Directors member Dawn Carter Bir, who has led numerous successful new product launches, including as Chief Commercial Officer of Reata Pharmaceuticals and as Vice President, Sales at Pharmacyclics, will support Dr. Grethlein in this interim role with additional oversight of the commercial business."

16:16 EDT KKR to acqurie Janney Montgomery Scott from Penn Mutual - The company states: "KKR announced the signing of a definitive agreement under which investment funds managed by KKR will acquire Janney Montgomery Scott LLC. Janney has over $150 billion in assets under administration, with more than 900 financial advisors providing financial planning, asset allocation, retirement planning and other financial advice and services to clients across 135 offices in the U.S. Following the close of the transaction, Janney will become a standalone private company that will continue to operate independently. The transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close in the fourth quarter of 2024."

16:12 EDT Mattel reports Q2 North American gross billings down 3%, international down 1% - Gross Billings in the North America segment decreased 3% as reported and in constant currency, due to declines in Infant, Toddler, and Preschool, Dolls, and Vehicles, partly offset by growth in Action Figures, Building Sets, Games, and Other. Gross Billings in the International segment decreased 1% as reported and were comparable in constant currency, due to declines in Dolls, and Action Figures, Building Sets, Games, and Other, partly offset by growth in Vehicles, and Infant, Toddler, and Preschool.

16:10 EDT Nuvation Bio announces updates, presentations for Taletrectinib - Nuvation Bio "announced multiple updates for its taletrectinib program. Data from the global, pivotal Phase 2 TRUST-II study has been accepted for an oral presentation at WCLC 2024 taking place September 7-10 in San Diego, California. Pooled data from both pivotal Phase 2 studies, TRUST-I and TRUST-II, has been accepted for a poster presentation at ESMO 2024 taking place September 13-17, in Barcelona, Spain. The pooled data presented at ESMO will support the Company's NDA in the United States. Additionally, the U.S. FDA has granted Orphan Drug Designation to taletrectinib for the treatment of multiple NSCLC indications, including ROS1-positive NSCLC."

16:09 EDT Nabors Industries sees Q3 Alaska, Gulf of Mexico combined adjusted EBITDA $20M - Sees Q3 lower 48 daily adjusted gross margin of $15,100-$15,200. Sees Q3 international market daily adjusted gross margin of $16,200-$16,300. Sees Q3 Capital Expenditures of $190M-$200M, with $80M-$85M for the newbuilds in Saudi Arabia.

16:08 EDT Alphabet declares cash dividend of 20c per share - Alphabet said: "Dividend payments to stockholders of Class A, Class B, and Class C shares were $1.2 billion, $173 million, and $1.1 billion, respectively, totaling $2.5 billion for the three months ended June 30, 2024. On July 23, 2024, Alphabet announced a cash dividend of $0.20 per share that will be paid on September 16, 2024, to stockholders of record as of September 9, 2024, on each of the company's Class A, Class B, and Class C shares."

16:08 EDT Tesla: Plans for new vehicles remain on track to start production in 1H25

16:06 EDT Tesla says focus remains on company-wide cost reduction - The company said: "Our focus remains on company-wide cost reduction, including reducing COGS per vehicle, growing our traditional hardware business and accelerating development of our AIenabled products and services. Though timing of Robotaxi deployment depends on technological advancement and regulatory approval, we are working vigorously on this opportunity given the outsized potential value. Concurrently, we are managing our product portfolio with a long-term orientation and focusing on growing sales, maximizing our installed base and generating sufficient cash flow to invest in future growth."

16:05 EDT Tesla still sees 'notably lower' volume growth rate for 2024

16:05 EDT Alphabet reports Q2 Google Cloud revenue $10.35B vs. $8.03B last year

16:03 EDT FTC Solar names Yann Brandt new President and CEO - FTC Solar announced that its Board of Directors has appointed Yann Brandt, a longtime solar executive, as the company's new President and Chief Executive Officer and a member of the Board, effective August 19, . His appointment has been made following a robust and competitive search process carried out by the Board with support from external resources. Shaker Sadasivam, Chairman of the Board of FTC Solar, said, "FTC has built a strong industry brand and foundation as a company, with a robust catalog of single-axis trackers for both 1P and 2P configuration with industry leading constructability and an enhanced cost structure. Following a thorough and highly competitive process to identify FTC Solar's next CEO, the Board finds that Yann is the right leader for FTC at this time, to execute on this foundation and capture the significant opportunity we see ahead. He is an exceptional, strategic leader and industry insider with deep experience and relationships throughout the solar industry. His focus on performance and delivery, with a firm understanding of the opportunities and challenges in the solar market, will serve FTC well as we continue to focus on execution and a healthy recovery. We are pleased to welcome him to the leadership team and Board."

16:01 EDT Cintas announces new $1B buyback authorization - Cintas announced that the Board of Directors approved an additional share buyback program under which the Company may buy up to $1.0 billion of Cintas common stock at market prices. This program is in addition to a current program with $0.5 billion of Cintas common stock remaining. Thus, in total, the Company may buy up to $1.5 billion of Cintas common stock at market prices.

14:48 EDT CSG reaffirms commitment to successfully completing $2.15B Kinetic acquisition - Czechoslovak Group, or "CSG," a global industrial holding company, which recently increased its offer for Vista Outdoor's The Kinetic Group to $2.15B, today reaffirmed its "strong commitment" to successfully completing the acquisition. CSG believes its fully financed bid maximizes the value that will be received by Vista Outdoor shareholders, and that the transaction can be completed in early August. "CSG's acquisition of The Kinetic Group is the optimal outcome for Vista Outdoor shareholders, employees of the company and the American economy. CSG is a highly experienced and globally respected industrial company and upon successful completion of the acquisition, we intend to fully integrate The Kinetic Group, build those businesses, serve all of the company's customers with the highest level of professionalism and trust, and add jobs in the United States. Once shareholder approval is secured, we stand ready to quickly close the transaction and begin to chart the future of the The Kinetic Group as part of CSG," said Michal Strnad, Chief Executive Officer and the owner of CSG.

14:29 EDT Crown Holdings CEO Donahue sells 15,000 common shares - In a regulatory filing, Crown Holdings president and CEO Timothy Donahue disclosed the sale of 15,000 common shares of the company on July 23 at a price of $85.03 per share.

13:07 EDT Golden Sun Health Technology Group Ltd trading halted, volatility trading pause

12:47 EDT Embraer sells six six A-29 Super Tucano to Paraguayan Air Force - Embraer announced the sale of six A-29 Super Tucano aircraft to the Paraguayan Air Force. "As a multi-mission aircraft, the A-29 provides the Air Forces with versatility for armed reconnaissance, close air support, light attack, and advanced training missions on a single platform, which exponentially increases the institutions' availability and operational flexibility. The operation, with deliveries scheduled from 2025, includes mission equipment and an integrated logistics services agreement," the company said in a statement.

12:18 EDT Wells Fargo board increases quarterly dividend 5c to 40c per share - Wells Fargo & Company announced its board of directors approved a quarterly common stock dividend of 40c per share, payable September 1, 2024, to stockholders of record on August 9, 2024. The third quarter dividend represents an increase of 5c per share, or 14%, from the prior quarter.

12:01 EDT Jumia Technologies falls -7.6% - Jumia Technologies is down -7.6%, or -$1.10 to $13.46.

12:01 EDT UPS falls -13.1% - UPS is down -13.1%, or -$19.07 to $126.11.

12:00 EDT KKR Real Estate Finance rises 12.8% - KKR Real Estate Finance is up 12.8%, or $1.29 to $11.38.

11:33 EDT SenesTech announces 1-for-10 reverse stock split - SenesTech announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:01 p.m, Eastern Time, on July 24, 2024. The company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "SNES" and will begin trading on a split-adjusted basis when the market opens on July 25. At the annual meeting of stockholders held on July 11, the company's stockholders granted the company's Board of Directors the discretion to effect a reverse stock split of the company's common stock through an amendment to its Amended and Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-20, with such ratio to be determined by the company's Board of Directors.

11:30 EDT Meta Platforms announces release of Llama 3.1 405B open source AI model - Meta (META) announced the release of Llama 3.1 405B, the first frontier-level open source AI model, as well as new and improved Llama 3.1 70B and 8B models. "In addition to having significantly better cost/performance relative to closed models, the fact that the 405B model is open will make it the best choice for fine-tuning and distilling smaller models," Meta CEO Mark Zuckerberg said in a blog post. "Beyond releasing these models, we're working with a range of companies to grow the broader ecosystem. Amazon (AMZN), Databricks, and Nvidia (NVDA) are launching full suites of services to support developers fine-tuning and distilling their own models." Zuckerberg said Meta is "committed to open source AI." Reference Link

11:20 EDT Snowflake, Meta team to host new flagship model family in Snowflake Cortex AI - Snowflake (SNOW) announced that it will host the Llama 3.1 collection of multilingual open source large language models in Snowflake Cortex AI for enterprises. This offering includes Meta's (META) most powerful open source LLM, Llama 3.1 405B, with Snowflake developing and open sourcing the inference system stack to enable real-time, high-throughput inference. "Snowflake's world-class AI Research Team is blazing a trail for how enterprises and the open source community can harness state-of-the-art open models like Llama 3.1 405B for inference and fine-tuning in a way that maximizes efficiency," said Vivek Raghunathan, VP of AI Engineering, Snowflake. "We're not just bringing Meta's cutting-edge models directly to our customers through Snowflake Cortex AI. We're arming enterprises and the AI community with new research and open source code that supports 128K context windows, multi-node inference, pipeline parallelism, 8-bit floating point quantization, and more to advance AI for the broader ecosystem."

11:18 EDT Nvidia announces Nvidia AI Foundry service, Nvidia NIM inference microservices - NVIDIA (NVDA) announced a new NVIDIA AI Foundry service and NVIDIA NIM inference microservices to supercharge generative AI for the world's enterprises with the Llama 3.1 collection of openly available models, also introduced today. "With NVIDIA AI Foundry, enterprises and nations can now create custom 'supermodels' for their domain-specific industry use cases using Llama 3.1 and NVIDIA software, computing and expertise. Enterprises can train these supermodels with proprietary data as well as synthetic data generated from Llama 3.1 405B and the NVIDIA Nemotron Reward model." "Meta's (META) openly available Llama 3.1 models mark a pivotal moment for the adoption of generative AI within the world's enterprises," said Jensen Huang, founder and CEO of NVIDIA. "Llama 3.1 opens the floodgates for every enterprise and industry to build state-of-the-art generative AI applications. NVIDIA AI Foundry has integrated Llama 3.1 throughout and is ready to help enterprises build and deploy custom Llama supermodels."

11:03 EDT Lockheed Martin: Demand for defense technology solutions 'robust' - Comments taken from Q2 earnings conference call.

10:54 EDT CareMax trading resumes

10:49 EDT CareMax trading halted, volatility trading pause

10:44 EDT Mira Pharmaceuticals Inc trading halted, volatility trading pause

10:40 EDT Ensysce Biosciences ready to commence PF614 Phase 3 trial in 2024 - Ensysce Biosciences,provides a Company review and update on the first half of 2024, including achievement of Breakthrough Therapy designation from the U.S. Food & Drug Administration. Recent clinical and development highlights: PF614: Successfully completed a PF614 End of Phase 2 meeting with the FDA, which provided guidance on strategy and design of the Phase 3 clinical program.; Published the results of clinical study P614-102, which determined that PF614 was bioequivalent to OxyContin, potentially allowing it to be developed through the shortened FDA 505(b)(2) regulatory pathway. The results were published in an article entitled 'Clinical evaluation of PF614, a novel TAAPa prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteers'. Established manufacturing partnerships with Societal CDMO, Porton Pharma Solutions, and Purisys LLC to position Ensysce for commercial scale production of PF614. PF614-MPAR: The FDA granted Breakthrough Therapy designation to PF614-MPAR, specifically acknowledging the potential impact of the innovative MPAR overdose protection technology. Breakthrough Therapy is an elite designation that expedites the development and review of drugs that are intended to treat a serious condition where the drug may demonstrate substantial improvement over available therapies. Applied for an additional $15 million non-dilutive grant funding from National Institutes of Health and National Institute on Drug Abuse to support three years of continued development for PF614-MPAR with a potential start date in the third quarter of 2024. Presented the clinical data for PF614-MPAR that resulted in the granting of Breakthrough Therapy designation at the NIH annual HEAL meeting, and the PF614-MPAR platform was recognized in the Trailblazer Session presented at the 2024 American Association of Pain Medicine annual meeting. Received guidance from the FDA for the efficient execution of the non-clinical program, potentially reducing required costs. Advanced the PF614-MPAR program in a continued collaboration with Quotient Sciences to undertake a second clinical trial, PF614-MPAR-102, anticipated to start in the fourth quarter of 2024. Opioid Use Disorder program: Achieved a major milestone in the Company's opioid use disorder program with selection of a lead drug candidate. The lead candidate PF9001, a TAAP methadone analogue, has shown lower potential of cardiovascular side effects associated with traditional methadone treatment. The OUD program is supported by non-dilutive grant funding through the Company's ongoing $15 million multi-year NIDA HEAL award.

10:35 EDT Eagle Bancorp increases quarterly dividend to 14.25c per share - Eagle's board of directors increased its quarterly cash dividend to $0.1425 per share on July 22, 2024. The dividend will be payable September 6, 2024, to shareholders of record August 16, 2024. The current dividend represents an annualized yield of 4.27% based on recent market prices.

10:30 EDT Denny's appoints Monigo Saygbay-Hallie as CPO, Patty Trevino as CBO - Denny's announced the appointment of two new executive leaders Monigo Saygbay-Hallie, Ph.D. joins as executive vice president, chief people officer for Denny's Corporation, effective August 5, and Patty Trevino joins as Denny's senior vice president, chief brand officer, effective August 12. Saygbay-Hallie will serve as executive vice president, chief people officer for Denny's Corporation at the enterprise level, leading people initiatives across Denny's and Keke's Breakfast Cafe. Saygbay-Hallie joins Denny's, having most recently served as chief people officer at Checkers & Rally's Drive-In restaurants. Trevino brings two decades of experience in the restaurant industry and most recently served as executive vice president, chief marketing officer at Red Lobster. Both roles will report to Kelli Valade, Denny's Inc. president and CEO.

10:20 EDT Cloudflare approves 2024 key executive change in control, severance policy - In a regulatory filing last night, Cloudflare disclosed that on July 17, the board of directors of the company adopted and approved the 2024 Key Executive Change in Control and Severance Policy, under which certain U.S. employees who are part of a select group of management or highly compensated employees may be designated as eligible to participate in the Policy and become eligible to receive certain severance payments and benefits in connection with certain qualifying terminations, which payments and benefits applicable to the participant are set forth in a participation agreement provided by the company. "The Company's named executive officers have been designated by the Board as eligible to participate in the Policy at the benefit levels described below, which are substantially the same payments and benefits, and on substantially the same terms and conditions, as our named executive officers are eligible to receive under the Company's current Change in Control and Severance Policy. The Policy will become effective on September 13, 2024, which is the day after the Expiring Policy expires by its terms," the filing noted. Cloudflare shares ar up 3% to $81.28 in early trading.

10:13 EDT Fly-E Group Inc trading halted, volatility trading pause

10:09 EDT Carnival announces order for three additional ships for Carnival Cruise Line - Carnival Corporation & plc announced an order for three new ships for its namesake Carnival Cruise Line brand for a new class of vessel, at nearly 230,000 gross registered tonnes. The agreement with Italian shipbuilder Fincantieri provides for the design, engineering, and construction of these liquefied natural gas-powered ships, which will be delivered in the summers of 2029, 2031 and 2033, respectively. With today's order, there have been five new ship orders for Carnival Cruise Line announced in 2024, the company said.

10:08 EDT Freeport-McMoRan says supply challenges continue - Says seen a couple of months of volatility in the market. Says world is getting more and more electrified. Says strategy is based on fundamentally positive outlook on long-term copper demand. Says construction is essentially complete on Indonesia smelter. Comments taken from Q2 earnings conference call.

10:01 EDT Banc of California falls -9.9% - Banc of California is down -9.9%, or -$1.45 to $13.23.

10:00 EDT HII unit awarded $65M contract - HII's Mission Technologies division was awarded a $65M task order to perform high-quality, specialized research and analysis for the Joint Staff J7, Deputy Director, Joint Warfighting Development. HII will support research and analysis in three areas. The first will focus on futures and concepts, to include developing a comprehensive view of the future operating environment. The second will focus on joint experimentation, to include informing and facilitating joint war gaming and integrated learning opportunities. The third will focus on wargaming for the Joint Staff J4 Logistics enterprise.

10:00 EDT MSCI rises 11.7% - MSCI is up 11.7%, or $59.37 to $565.39.

09:57 EDT GM Defense Canada receives C$35.8M contract award from CAF - GM Defense Canada, a subsidiary of GM Defense, has been awarded a C$35.8M contract by the Canadian Armed Forces for 90 light tactical vehicles, with an option to procure up to an additional 18 LTVs. GM Defense Canada will also deliver training, technical manuals and additional vehicle content sourced from Canadian companies. As part of the contract, GM Defense Canada is providing both nine-passenger LTVs and a new utility variant of the LTVs that leverage the design of a proven solution currently fielded with the U.S. Army. GM Defense Canada's LTVs will support the NATO Enhanced Forward Presence Multinational Battlegroup in Latvia. The vehicles will enable Soldiers to move with increased speed, range and safety across complex terrain.

09:50 EDT Qatar Airways announces order for 20 more Boeing 777-9 passenger jets - Boeing and Qatar Airways announced the Middle Eastern airline placed an order for 20 more 777-9 airplanes. The order, which expands the carrier's 777X order book to nearly 100 airplanes, was finalized this year and listed as unidentified on Boeing's Orders & Deliveries website. "Qatar Airways is proud to announce an expansion to the existing Boeing 777X aircraft order with an additional 20, totalling 94 Boeing 777X aircraft," said Qatar Airways Group CEO, Engr. Badr Mohammed Al-Meer.

09:48 EDT Webster Financial falls -10.5% - Webster Financial is down -10.5%, or -$5.12 to $43.67.

09:47 EDT MSCI rises 8.8% - MSCI is up 8.8%, or $44.47 to $550.49.

09:47 EDT Spotify rises 14.7% - Spotify is up 14.7%, or $43.34 to $338.79.

09:43 EDT Wheeler Real Estate Investment Trust trading resumes

09:32 EDT Trust Stamp partners with Botdoc for ID security in the automotive industry - Trust Stamp announces a partnership with Botdoc to integrate Trust Stamp's low-code Orchestration Platform within the Botdoc Connect product, providing robust Identity Verification and KYC. The integration includes document validation using the Driver License Data Verification System offered by the American Association of Motor Vehicle Administrator and accessed by Trust Stamp under a license from AAMVA.

09:28 EDT Nisun International signs egg distribution agreement with ZTO Yunpei in China - Nisun International announced a milestone in its partnership with Zhejiang ZTO Yunpei, the supply chain company under ZTO Express, a logistics company in China. ZTO Yunpei has signed a purchase agreement with Nisun International in China's egg market. Under the agreement, Nisun International has supplied eggs to ZTO Yunpei for distribution to its customers, resulting in sales exceeding $68.7M to date. Nisun International's accumulated sales from eggs have reached over $687.9M. This collaboration is expected to drive significant growth for both companies, capitalizing on the increasing demand for eggs in China.

09:17 EDT Mullen Automotive's Bollinger announces warranty coverage for B4 Chassis Cab - Mullen Automotive's Bollinger Motors releases its full warranty coverage on the Bollinger B4 Chassis Cab, the company's all-new, all-electric Class 4 commercial truck. Under the warranty, Bollinger will provide comprehensive, competitive coverage for: Bumper-to-bumper: 3-year/36,000-miles; Powertrain: 5-year/50,000-miles; High-voltage battery: 8-year/100,000-miles; Air conditioning: 5-year/50,000-miles; Frame rails and cross-members: 5-years/unlimited miles; Corrosion: 5-years/unlimited miles; Tires: 4-years/unlimited miles.

09:15 EDT Cleveland-Cliffs CEO says 'Mike Pompeo is damaged goods' - Cliffs' (CLF) Chairman and CEO Lourenco Goncalves was speaking on the company's earnings call, referencing Nippon Steel (NPSCY) having hired former Secretary of State Mike Pompeo to help complete a proposed purchase of U.S. Steel (X).

09:12 EDT PacBio announces Novogene is using its Revio - PacBio announced that Novogene is using its Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany, serving customers across the European scientific community. Novogene is a leading provider of genomic services and bioinformatics expertise, working with a wide range of leading research institutions, clinical and commercial organizations. The increased accuracy and throughput offered by the Revio are designed to enable Novogene's customers to scale in-depth genomic research across rare diseases, cancer, microbes, and agriculture in a cost-effective way.

09:10 EDT Backblaze names Wakeam as Chief Revenue Officer - Backblaze announced the appointment of Jason Wakeam as the company's first Chief Revenue Officer, CRO. Wakeam previously served as a vice president of global sales at SnapLogic.

09:09 EDT Dorman Products appoints Whitelam as VP, Investor Relations, Risk Management - Dorman Products (DORM) announced the addition of Alexander Whitelam as Vice President, VP, Investor Relations & Risk Management. Alex joins the Company after serving most recently as Head of Investor Relations at SEI Investments Company (SEIC)

09:08 EDT Ibex launches Wave iX Translate - ibex announced the launch of Wave iX Translate, which breaks through the language barrier to enable real-time customer conversations and interactions in more than 150 languages, without requiring native speakers. Leveraging Wave iX Translate, agents and customers speak or type in their native language, which is then translated in real-time for understanding both parties. With Wave iX Translate, businesses can overcome language barriers and adapt to local accents and nuances, and deliver an enhanced customer experience. This elevated experience helps to cultivate deeper connections with customers.

09:07 EDT Vestis appoints Bill Seward as Chief Operating Officer, Rego SVP of Sales - Vestis Corporation announced the appointment of Bill Seward as Chief Operating Officer or COO, effective September 1 and Peter Rego as Senior Vice President of Sales, effective immediately. Reporting directly to CEO Kim Scott, both Seward and Rego will assume responsibility for key aspects of the company's strategic plan to achieve high-quality growth, efficient operations, disciplined capital allocation and a performance-driven culture. Additionally, the Company has aligned its field organizational structure to support faster and sustainable adoption of programs and procedures that enhance the customer and teammate experience

09:06 EDT Progress Software introduces MarkLogic FastTrack - Progress announced the availability of Progress MarkLogic FastTrack, a UI toolkit for building data- and search-driven applications to visually explore complex connected data stored in Progress MarkLogic platform. Applications built with MarkLogic FastTrack UI toolkit help data users, analysts and decision-makers uncover unique insights and relationships through interactive, user-friendly and visually rich interfaces. While organizations add more diverse data types to provide context for business analytics, they struggle to gain deep insights as most business intelligence tools can visualize one aspect of data at a time, giving only a partial representation of what's going on. Data and analytics leaders must bridge the gap between the analytics of today and the context-enriched analysis their industry demands.

09:04 EDT Pearson appoints Ginny Cartwright Ziegler as Chief Marketing Officer - Pearson (PSO) announces the appointment of Ginny Cartwright Ziegler as Chief Marketing Officer. Ginny will report to CEO Omar Abbosh and will lead the next generation of the company's work in marketing, brand and communications, effective 29 July 2024. Ginny succeeds Lynne Frank, who is stepping down from her dual role as Chief Marketing Officer and Co-President, Direct to Consumer...Ginny comes to Pearson from Accenture (ACN), where she was most recently the Chief Marketing Officer for North America, which is the company's largest business and represents half its revenue. Ginny was pivotal in driving double-digit growth over four years and creating a collaborative and purpose-focused culture. Prior posts during her 16-year career at Accenture included leading global teams that catapulted the company's cloud practice to the top market position and generated triple-digit growth for its cybersecurity and talent and organization businesses.

09:04 EDT Beyond Meat debuts new product Beyond Sun Sausage - Beyond Meat debuted a new product line with the introduction of Beyond Sun Sausage. "We're thrilled to introduce a completely new innovation to the plant-based category with the addition of our wholesome, flavor-forward Beyond Sun Sausage," said Dariush Ajami, Chief Innovation Officer, Beyond Meat. "Filled with clean, plant proteins including yellow peas, brown rice, faba beans and red lentils, this launch further exemplifies our industry-leading commitment to raising the nutrition bar for plant-based meats and creating delicious, healthy products."

09:03 EDT Eightco Holdings achieves revenues of $100M in mobile phone business - Eightco (OCTO) announced that its wholly-owned subsidiary, Forever 8 Fund, has reached $100 million in revenues from its refurbished Apple (AAPL) smartphone division since launching in April 2021. "We are excited to have reached this milestone of $100 million in revenue from our refurbished Apple smartphone division," said Paul Vassilakos, CEO of Eightco and President of Forever 8. "Continued growth in the refurbished market for Apple products, combined with Forever 8's unique offering, is driving strong growth for our Company in this sector. We continue to see significant demand from both our suppliers and customers. As we continue to scale our business in the refurbished iPhone market, we are also exploring opportunities to expand into other Apple product categories, positioning Forever 8 for even greater success."

09:00 EDT UPS says plans to exit the year with operating margin of 10% - Says well on the way of achieving FY24 GAAP revenue target. Says on plan to complete additional five operational closures in second half of the year. Says currently experiencing volume momentum. Says growth rate will not be as high as it was at the beginning of the year. Says plans to exit the year with operating margin of 10%. Says with pending sale of Coyote expects to have more cash. Says expects tax rate to be 22% for remainder of the year. Says domestic volume performance impacts were customers favoring more economical products and new e-commerce customers running a different model. Says expects mix to rationalize as the company moves towards the end of the year. Comments and guidance taken from Q2 earnings conference call.

08:55 EDT ChromaDex launches Niagen+ NAD+ Test Kit available exclusively to HCPs - ChromaDex launches the Niagen+ NAD+ Test Kit , now available exclusively through the company's healthcare practitioner HCP channel. This innovative test kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, helping them create more personalized and effective patient protocols using ChromaDex's NAD+-boosting HCP products, Tru Niagen and Niagen+. Tru Niagen is a suite of oral dietary supplements featuring Niagen (patented nicotinamide riboside or NR, the most efficient and high-quality NAD+ precursor available. Niagen+ features pharmaceutical-grade Niagen, patented nicotinamide riboside chloride or NRC, and will soon be available as Niagen IV and injections exclusively at clinics from U.S. FDA 503B-registered outsourcing facilities with a prescription. Representing a significant advancement in intravenous NAD+ therapy, practitioners are eager to provide Niagen IV therapy to patients.

08:54 EDT Fanhua announces completion of share option cash exercises - Fanhua announced that all share options previously granted to its key employees by the Board of Directors have recently been fully exercised through cash payment at an exercise price of $1.92 per American Depository Share, representing a premium of approximately 21.4% from the Company's closing price on the last trading day prior to the cash exercise. This move not only highlights its key employees' strong confidence in the Company's future development but also demonstrates their commitment to growing with the company and sharing in its success. As previously disclosed, on July 2, 2024 the Board authorized the issuance of share options to purchase up to 138,000,000 ordinary shares, representing 6,900,000 ADSs of the Company, to 15 management team members of the Company's major subsidiaries, to align their interests with the long-term success of the Company. Upon cash exercise of the share options, these key employees collectively held approximately 10.8% of the Company's shares. The Company offered several of these key employees a loan at an interest rate of 3% per annum to facilitate the exercise of the share options. They also committed to serving the Company for no less than three years.

08:52 EDT Evogene to implement 1-for-10 reverse share split - Evogene announced that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on July 24. The company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-reverse split basis at the market open on July 25, and on the Tel Aviv Stock Exchange at the market open on July 28, in each case under the company's existing trading symbol "EVGN". Following the implementation of the reverse split, the company's registered share capital, which as of the date hereof consists of NIS3M divided into 150,000,000 Ordinary Shares of NIS0.02 par value each, will be adjusted to consist of NIS3M divided into 15,000,000 Ordinary Shares of NIS0.2 par value each. The reverse split will adjust the number of issued and outstanding Ordinary Shares of the Company from approximately 50,790,000 Ordinary Shares to approximately 5,079,000 Ordinary Shares.

08:52 EDT Conduent modernizes Ohio turnpike's tolling lanes to improve motorist experience - Conduent Transportation announced the completion of a modernized toll collection infrastructure for the Ohio Turnpike. Conduent upgraded 216 lanes on the 241-mile-long turnpike to include self-service and collector-operated toll plazas, as well as open-road, automated tolling options for vehicles using E-ZPass transponders...Westgate toll plaza ...The new system, managed by the Ohio Turnpike and Infrastructure Commission OTIC , will help increase traffic flow and vehicle throughput, while providing for operational efficiencies - all leading to more convenience and an improved experience for motorists. According to OTIC, the modernization is the largest construction project in Ohio Turnpike history since the toll road was completed in 1955..."Since 2020, our team has partnered with OTIC to make this new tolling infrastructure a reality, and we are proud to complete such an important project on one of the longest-running toll roads in the country," said Adam Appleby, Group President, Public Sector Solutions. "Today's announcement reinforces our leadership in providing tolling solutions that bring lasting value for agencies and the customers who experience the true benefits of modern mobility." This Ohio project follows another recently announced implementation, in which Conduent launched an Express Lanes tolling system for the Virginia Department of Transportation VDOT. That system enables flexible, dynamic pricing and license plate image reviews, helping to improve the flow of traffic and relieve congestion for VDOT.

08:51 EDT Freeport-McMoRan sees Q3 copper sales 1.01B lbs. - Sees Q4 copper sales 1.04B lbs. Sees Q3 gold sales 475,000 oz., Q4 gold sales 425,000 oz. Sees Q3 moly sales 20M lbs., Q4 moly sales 21M lbs.

08:48 EDT Cleveland-Cliffs CEO says Mexico continues to be 'a problem' in steel market - Mexico continues to aid foreign companies to dump steel in the domestic market, says Cliffs' Chairman and CEO Lourenco Goncalves on the company's earnings call.

08:44 EDT Freeport-McMoRan sees FY24 CapEx $3.7B ex. Indonesia downstream projects - Sees 2024 copper sales 4.1B lbs., 2025 copper sales 4.2B lbs and 2026 copper sales 4.3B lbs. Sees 2024 gold sales 1.8M ozs, 2025 gold sales 1.5M ozs. and 2026 gold sales 1.5M ozs. Sees 2024 molybdenum sales 82M lbs., 2025 molybdenum sales 90M lbs. and 2026 molybdenum sales 90M lbs. Sees 2025 Capex $4.1B. Comments taken from presentation slides for Q2 earnings conference call.

08:40 EDT General Motors says EV portfolio scaling well, taking market share - Says EV portfolio growing faster than the market. Says barriers to EV adoption improving. Says past investments producing well-performing portfolio. Says China market will "remain challenging" for remainder of year. Comments taken from Q2 earnings conference call.

08:38 EDT Arrow Financial to unify bank subsidiaries into entity named Arrow Bank - Arrow Financial has finalized plans to unify its banking subsidiaries, Glens Falls National Bank and Trust Company and Saratoga National Bank and Trust Company, into one entity to be renamed Arrow Bank. This announcement follows the necessary public comment period and regulatory approval by the Office of the Comptroller of the Currency. Under its new name, Arrow Bank will continue to be part of Arrow Financial. The leadership team will remain unchanged. Customers can continue to use all the same bank branch locations, and staffing will not be affected. Arrow Bank will begin rolling out its new branding as part of the unification process. Collectively, the banks operate 37 branches in northeastern New York, stretching from Albany to Clinton counties. Arrow currently has an asset size of approximately $4.2B and more than 550 employees.

08:38 EDT Tian Ruixiang regains compliance with Nasdaq's periodic filing requirement - Tian Ruixiang announced that the Company received a written notification from the Nasdaq Stock Market on July 18, 2024, informing the Company that it has regained compliance with Nasdaq's periodic filing requirement set forth under Listing Rule 5250(c)(1), because the Company had filed its annual report on Form 20-F for the period ended October 31, 2023 on July 17, 2024.

08:37 EDT GM's Cruise team to focus next autonomous vehicle on next-gen Chevrolet Bolt - In a letter to shareholders, GM CEO Mary Barra said "Cruise has returned to the road in Houston, Phoenix and Dallas and we recently made several significant leadership appointments, including hiring Marc Whitten as CEO. Marc has decades of experience on the frontlines of technology transformations. The Cruise team will also simplify their path to scale by focusing their next autonomous vehicle on the next-generation Chevrolet Bolt, instead of the Origin. This addresses the regulatory uncertainty we faced with the Origin because of its unique design. In addition, per-unit costs will be much lower, which will help Cruise optimize its resources."

08:37 EDT Blockchain Intelligence Group adds additional modules - Blockchain Intelligence Group announces the launch of two new advanced modules for its Certified Cryptocurrency Investigator training program. The additions include Module 9: Hacks and Exploits in the Cryptocurrency Space and Module 10: Cryptocurrency Compliance and Risk Management for Financial Institutions.

08:36 EDT Cleveland-Cliffs sees Q3 steel shipments of about 4.0 million net tons - Sees Q3 steel unit costs $30/t reduction from Q2 to Q3. Guidance from earnings call presentation slides.

08:35 EDT Cleveland-Cliffs says year-over-year cost reduction targets remain on track - In earnings slides related to the company's "top priorities," Cleveland-Cliffs says year-over-year cost reduction targets remain on track and that it expects to quickly deleverage its balance sheet following the Stelco acquisition, which it expects to close in the fourth quarter of 2024.

08:33 EDT FactSet appoints Shan as CFO - FactSet announced that Helen Shan, a FactSet executive who currently serves as Executive Vice President and Chief Revenue Officer, has been appointed Chief Financial Officer, CFO, effective immediately. Shan succeeds Linda Huber, who is transitioning out of the Company. Huber's departure is not the result of any disagreement with the Company regarding its accounting practices, financial statements or financial condition, or any of the Company's related disclosures. FactSet today reaffirmed its full year fiscal 2024 guidance, as previously provided on June 21, 2024.

08:32 EDT Adial Pharmaceuticals advances second cohort in PK study of AD04 - Adial Pharmaceuticals announced the progression to the second cohort in the pharmacokinetics, PK, study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder, AUD, in heavy drinking patients, following the successful completion of the first cohort. Topline results from both cohorts are expected to be announced during the fourth quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial commented, "We are pleased with the progress of our pharmacokinetics study of AD04. The successful completion of the first cohort allows us to advance to the second cohort as planned, staying on track with our projected timeline. The results from both cohorts will offer invaluable insights that are critical for the design of our upcoming Phase 3 Clinical Trial. We anticipate engaging with the FDA following receipt of the topline data from this study and seek their feedback on the overall design of our Phase 3 program."

08:26 EDT Ormat Technologies secures 15-year RA agreement with City of Riverside - Ormat Technologies announced the signing of a 15-year Resource Adequacy Purchase and Sale Agreement, RA Agreement, with the City of Riverside for the 80MW/320MWh Shirk Battery Energy Storage System, BESS, located in Visalia, California. The Shirk project, which is currently expected to be eligible for a 40% Investment Tax Credit, represents Ormat's continued commitment to strategically growing its Energy Storage segment in the key California energy market. The agreement is Ormat's first storage contract with the City of Riverside and is the City's first long-term RA Agreement. Critically, included in the RA Agreement is a guaranteed commercial operation date of March 1, 2026, that the Company currently believes can be achieved by the end of 2025. This highlights Ormat's enhanced and differentiated execution capabilities as the Company continues to build its pipeline of energy storage projects and transitions to a more stable and profitable portfolio.

08:25 EDT Ovid Therapeutics expands scientific advisory board - Ovid Therapeutics announced it has significantly expanded its SAB with the appointment of renowned neurologists, neuroscientists, and epileptologists. The new SAB members were appointed to advise Ovid on the potential application of its unique pipeline programs and mechanisms of action to broader areas of neurology in which they may offer therapeutic promise. The SAB is chaired by Professor Robert Langer, who convened the first meeting of the expanded SAB at Massachusetts Institute of Technology in July 2024. Members of the Ovid Therapeutics Scientific Advisory Board: Robert Langer; Imad Najim; Raman Sankar; Jamie Maguire; Jeffrey Noebels.

08:22 EDT Fiverr launches summer product release - Fiverr launches its new summer product release, commencing its expansion from a services marketplace to a hiring platform. "Major shifts in the workplace, including heightened focus around skills and upskilling, diverse new roles from seasoned fractional executives to first-time side hustlers, and the introduction of new technologies, demands new solutions," said Micha Kaufman, founder and CEO of Fiverr. "Today's new releases are providing an expanded breadth of options for businesses of all sizes to recruit skilled talent and integrate freelancers into their workforce. By elevating how freelancers are featured to include their full set of skills and providing flexible options for working hourly, hiring managers and businesses can better recruit the talent they need."

08:21 EDT Captivision announces strategic improvements to balance sheet - Captivision announced strategic improvements to its balance sheet, resulting in a strengthening of its financial position. The Company entered into contribution agreements with certain creditors of its wholly owned subsidiary, Captivision Korea pursuant to which the Contributors agreed to contribute the respective outstanding balances remaining under various debt agreements with Captivision Korea to the Company in exchange for the issuance by the Company of its ordinary shares in a debt to equity conversion transaction. Pursuant to the Conversion, an aggregate of KRW 5,791,867,301 of Contributed Debt was contributed to the Company in exchange for the issuance of an aggregate of 1,414,895 shares at a conversion price per share equal to $3.00. Captivision Korea entered into a Private Bonds Subscription Agreement with certain investors, pursuant to which the Subscribers agreed to subscribe to and Captivision Korea agreed to issue an aggregate amount of KRW 3,100,000,000 of unregistered private placement bonds.

08:19 EDT Bionano Genomics announces publication of first multi-site study on OGM - Bionano Genomics announced the publication of the first multi-site study in multiple myeloma comparing optical genome mapping, OGM, to traditional cytogenetic methods for the detection of structural variants. Key findings: Compared to FISH, OGM achieved 100% sensitivity, specificity, and accuracy in cases after CD138 selection and 96.6% sensitivity, 100% specificity, and 98.3% accuracy in unselected cases; OGM detected gains of chromosome 1q in several samples, a known high-risk factor in MM; OGM revealed 18 hyperdiploidy, 4 hypodiploidy, and 9 IGH or MYC rearrangements undetected by FISH; In 18% of cases, OGM identified chromoanagenesis that was undetected by FISH; In 18% of cases, OGM changed the prognostication beyond that indicated by standard cytogenetics/FISH analysis; OGM detected 366 novel structural variants and copy number variants that are potentially relevant to the formation and development of MM.

08:18 EDT 180 Life Sciences granted additional extension by Nasdaq to regain compliance - 180 Life Sciences received notice from the Nasdaq Listing Qualifications Panel of The Nasdaq Stock Market that the Hearings Panel has granted the Company's request for additional time to achieve compliance with Nasdaq's continued listing rules and demonstrate long-term compliance with the Equity Rule. Specifically, the Hearings Panel has agreed to provide the Company until September 20, 2024 to regain compliance with the Equity Rule and to allow the continued listing of the Company's common stock and warrants on The Nasdaq Stock Market through such date, subject to the Company's compliance with the Equity Rule on or prior to such date. The Company is currently out of compliance with Listing Rule 5550(b)(1), which requires listed issuers to maintain minimum stockholders' equity of $2.5 million and does not meet any of the alternative standards in Listing Rule 5550(b). As previously disclosed, on November 15, 2023, the Listing Qualifications department of Nasdaq notified the Company that it did not comply with the Equity Rule and Nasdaq subsequently provided the Company an extension until May 13, 2024, to regain compliance with the Equity Rule.

08:17 EDT Spectral adds three new clinical trial sites to expedite ED patient enrollment - Spectral AI announced that it has added three new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: University Medical Center, UMC, Burn Center at Texas Tech University Health Sciences Center led by principal investigator Alan Pang, M.D., Tampa General Hospital Burn Center led by principal investigator Jared Troy, M.D., and University of South Alabama, USA, Health Emergency Department led by Andrew Bright, D.O. These new locations expand the total number of U.S. Clinical Trial Sites to 16, comprised of both burn centers and Emergency Departments, EDs. The 2024 U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by Spectral AI's DeepView System for burn indication. The study is expected to be the final clinical trial before the Company seeks FDA approval of its DeepView System for burn indication in 2025.

08:16 EDT CareCloud says Series A proxy reveals 'encouraging trend' - CareCloud continues to solicit proxies from the holders of its 11% Series A Cumulative Redeemable Perpetual Preferred Stock to approve an amendment to the Company's Certificate of Designations, Preferences and Rights of its Series A Preferred Stock. With approximately 11% of the shares of Series A Preferred Stock having provided their voting instructions by proxy to date, the Company's Board of Directors is encouraged to see that approximately 72% of these shares are in favor of the changes recommended in the Preferred Stock Proposal. "This is an important vote for Series A Preferred Shareholders," said Stephen Snyder, President of CareCloud. "To become effective, the proposal needs the affirmative vote of at least two-thirds of the shares of all outstanding Series A Preferred Stock - or about 3 million of the outstanding 4.5 million shares. Series A Preferred Shareholders who would like to submit their voting instructions can do so now through August 21, 2024, by calling 844-874-6164, by visiting www.aalvote.com/ccld, or by mailing back the completed proxy card received from the Company. If you vote by phone or over the internet, you will need your control number from your proxy card. However, those who would instead prefer to attend the Special Meeting in person can do so by following the instructions contained in the Definitive Proxy materials filed with the SEC." If the Preferred Stock Proposal is ultimately approved, holders of Series A Preferred Stock would receive similar change of control protections to those afforded to holders of the Company's Series B 8.75% Cumulative Redeemable Perpetual Preferred Stock. Also, the dividend of Series A Preferred Stock would mirror that of the Series B Preferred Stock, and the Company would, going forward, have the right to exchange the shares of Series A Preferred Stock for common stock at the liquidation preference value of the $25/share, plus accrued and unpaid dividends.

08:15 EDT GCT Semiconducto & Ligado announce commercial availability of Band 54 modules - Ligado Networks and GCT Semiconductor Holding announced today that GCT's Luna Cat-12 LTE module is now commercially available after clearing Federal Communications Commission FCC certification. The module is a foundational technology for a new ecosystem of commercial devices operating on LTE Band 54 spectrum at 1670-1675 MHz. GCT's GCM4701NA module advances the LTE Band 54 ecosystem, creating new opportunities for the critical infrastructure industry, including utilities and enterprises building robust private networks. The module contains GCT's GDM7243A chipset and provides 4G LTE onnectivity for a broad range of devices built by original equipment manufacturers serving these market segments. "Band 54 stands out as a highly distinctive mid-band spectrum resource for the utility and enterprise segments - a 3GPP-standardized and a fully-licensed 5-MHz TDD block available nationwide," said Sachin Chhibber, Chief Technology Officer at Ligado Networks. "Licensed spectrum assures availability and enhances security to enable more robust and secure private networks. The Luna module's availability marks a major milestone in ecosystem support for the spectrum."

08:13 EDT Arcutis Biotherapeutics submits sNDA for ZORYVE foam to FDA - Arcutis Biotherapeutics announced the submission of a supplemental New Drug Application for ZORYVE foam 0.3%, a once-daily, next generation phosphodiesterase-4 inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis. The submission is supported by positive results from Arcutis' pivotal ARRECTOR Phase 3 trial, a Phase 2b study, and long-term efficacy and safety data generated from the ZORYVE cream development program in plaque psoriasis. The "A Randomized tRial Employing topiCal roflumilasT foam to treat scalp psORiasis" study was a parallel group, double-blind, vehicle-controlled pivotal Phase 3 study of the safety and efficacy of roflumilast foam 0.3% or a matching vehicle administered once-daily in individuals with plaque psoriasis of the scalp and body ages 12 and older. The study met its co-primary endpoints with 67.3% of individuals treated with roflumilast foam achieving Scalp-Investigator Global Assessment Success compared to 28.1% of individuals treated with a matching vehicle foam at Week 8, and 46.5% of individuals treated with roflumilast foam achieved Body-Investigator Global Assessment Success compared to 20.8% of individuals treated with a matching vehicle foam at Week 8. Two thirds of roflumilast-treated patients with clinically meaningful itch at baseline achieved a clinically significant reduction in itch compared to 30.3% of vehicle-treated patients at Week 8 as measured by a greater than or equal to 4-point change from baseline in Scalp Itch-Numeric Rating Scale. Importantly, some patients experienced rapid relief in scalp itch 24 hours following first application compared to vehicle. In addition, improvement in body itch as measured by the Worst Itch-Numeric Rating Scalewas also observed at Week 8, with 63.1% of those treated with roflumilast foam achieving a greater than or equal to 4-point reduction in WI-NRS compared to 30.1% of those treated with vehicle, as well as Week 2. Roflumilast foam 0.3% was well tolerated. The incidence of Treatment Emergent Adverse Events was low and generally similar between active treatment and vehicle, with most TEAEs assessed as mild to moderate severity. Overall, the most common adverse reactions for roflumilast foam in the phase 3 and phase 2b studies included headache, diarrhea, nausea, and nasopharyngitis. Rates of discontinuation due to adverse events were low and similar among roflumilast-treated and vehicle-treated patients.

08:12 EDT Trinity Capital launches new vehicle in partnership with Eagle Point Credit - Trinity Capital has launched a new vehicle in partnership with Eagle Point Credit. Trinity's wholly owned registered investment adviser will be an adviser to the new vehicle, thereby bolstering the company's sources of capital for lending and generating non-capital intensive fee income. The vehicle is being capitalized with an equity commitment of $60M and has the ability to use leverage. It is intended for the vehicle to ultimately be converted into a private business development company. The vehicle is generally expected to invest ratably in opportunities originated by the Trinity platform.

08:12 EDT USPTO grants Azitra patent for future potential pipeline candidates for AD - Azitra announced that the U.S. Patent and Trademark Office or USPTO has granted U.S. patent No. 12,036,248, covering future potential pipeline candidates for indications including atopic dermatitis, titled "Therapeutic treatment of skin disease with recombinant skin microorganisms." The Company also announced three additional newly allowed patents in three countries, including the U.S., Canada, and China: Methods and Compositions for Treating Inflammatory Skin Disease with Recombinant Microorganisms U.S. Patent Application No. 16/121,903... Covers the composition of filaggrin-secreting strains of Staphylococcus epidermidis Methods and Compositions for Treating Atopic Dermatitis with Recombinant Microorganisms Canadian Patent Application No. 3067364 Covers the use of filaggrin-secreting strains of Staphylococcus epidermidis for atopic dermatitis and other skin diseases... Methods and Compositions for Treating Inflammatory Skin Disease with Recombinant Microorganisms Chinese Patent Application No. 201880071303.9 Covers the composition of filaggrin-secreting strains of Staphylococcus epidermidis..Travis Whitfill, Azitra's COO, co-founder, and inventor of the patents stated, "We are delighted to announce our second US patent issuance this year and three additional patent allowances in key markets in the U.S., Canada, and China. The indication addressed by the newly issued U.S. patent, atopic dermatitis, affects approximately 16.5 million people in the United States. There are numerous diseases associated with filaggrin deficiency, and the newly issued U.S. patent extends our protection to include a major market in the U.S., atopic dermatitis, particularly those with mild to moderate disease. Additionally, the new patent allowances in China and Canada extend our IP strength globally."

08:10 EDT GE HealthCare, Volta Medical enter into joint development agreement - Volta Medical announced a Joint Development Agreement with GE HealthCare. Through this collaboration, Volta aims to integrate its latest AI solution, the Volta AF-Xplorer, with GE HealthCare's latest digital platform, Prucka 3 and CardioLab EP Recording system. The combined solutions are expected to enhance performance and streamline workflows for electrophysiologists during catheter ablation procedures to treat atrial fibrillation. Volta Medical's AI solution is designed to assist electrophysiologists in real-time assessment of dispersed electrograms. This aligns with GE HealthCare's CardioLab EP Recording system's signal clarity. In bringing these technologies together, the companies aim to help physicians optimize management of AFib by integrating advanced EP recording capabilities with AI-driven dispersion information.

08:09 EDT NV5 Global awarded $5M NOAA contract for Lake Michigan survey - NV5 Global announced that it has been awarded a $5M contract by the National Oceanic and Atmospheric Administration, NOAA, Office of Coast Survey to conduct a comprehensive hydrographic survey in Lake Michigan. "NV5's geospatial marine surveying business continues its strategic expansion into new geographies to support water resource management, maritime safety, and updated navigational information," said Dickerson Wright, PE, Executive Chairman of NV5. "NV5's specialized expertise in hydrographic surveying and nautical charting makes us uniquely qualified to support commercial and recreational maritime safety efforts by providing essential data for updated National Ocean Service (NOS) nautical charts."

08:08 EDT LXP Industrial Trust partner with Wunder to deploy solar at Chicago property - LXP Industrial Trust partnered with Wunder to deploy an on-site solar system at LXP's Rockford, Illinois industrial facility. The 207 kilowatt solar system, which came online in June 2024, is expected to deliver substantial energy bill savings to the tenant. The system is anticipated to generate 261,990 kilowatt hours of power in its first year of operation alone, offsetting more than 403,500 pounds of CO2 emissions.

08:06 EDT RTX's GTF engine for A320neo Airbus selected by Chile's Sky Airline - RTX (RTX) business Pratt & Whitney announced that Chilean-based Sky Airline has entered into a memorandum of understanding to select the GTF engine to power 10 firm Airbus (EADSY) A321XLR aircraft, with options for 29 Airbus A320neo and A321neo aircraft. With this selection, Sky Airline becomes a first-time Pratt & Whitney customer. Pratt & Whitney plans to provide long-term maintenance services via an EngineWise Comprehensive service agreement. Founded in Chile in 2001, Sky is a low-cost airline that operates a fleet of Airbus A320/A321neo aircraft.

08:04 EDT Trailblazer Merger I enters business combination agreement with Cyabra - Cyabra Strategy and Trailblazer Merger Corporation I announced the signing of a definitive agreement for a business combination that upon closing is expected to result in Cyabra being publicly listed on the NASDAQ. The spread of disinformation is one of the most pressing challenges facing society today, undermining trust in brands, individuals, communities, and democratic institutions. At a time when students are bullying their peers using AI generated fake content and automated distribution bots, nation states disseminate false narratives to impact public opinion on elections and military conflicts, and mega corporations spread misinformation about competitors, impacting tens of thousands of workers and shareholders for financial profit, Cyabra is on the front lines of this informational warfare, identifying illicit bot campaigns and providing tools to combat the bad actors in the ongoing fight to restore trust in the digital realm. The transaction values Cyabra at a total enterprise value of $70 Million at signing. Upon the closing of the transaction, which is expected in the first quarter of 2025, the combined company will operate as Cyabra and will be listed on NASDAQ. The transaction has been unanimously approved by each of Trailblazer's and Cyabra's Board of Directors. The proposed transaction is subject to the approval of Trailblazer and Cyabra stockholders and the satisfaction or waiver of other customary closing conditions, including a registration statement being declared effective by the U.S. Securities and Exchange Commission

08:03 EDT Lucid Diagnostics announces record quarterly EsoGuard test volume - Lucid Diagnostics (LUCD), a majority-owned subsidiary of PAVmed (PAVM), announced that it performed a record number of commercial EsoGuard Esophageal DNA tests in the second quarter of 2024. The 3,174 tests represent a 31% increase sequentially from the first quarter. Lucid also reported that it held a productive meeting with CMS Medicare Administrative Contractor Palmetto GBA's Molecular Diagnostics Program.

07:47 EDT SunCar Technology, Lotus Technology partner in automotive industry service - SunCar Technology (SDA) announced a strategic partnership with Lotus Technology (LOT) to enhance automotive industry services. This collaboration will leverage SunCar's auto e-insurance technology platform and its automotive service network to support and optimize Lotus's market expansion, offering Lotus owners one-stop automotive services. SunCar will utilize its cost advantages in the insurance industry and nationwide agency network to provide Lotus customers with a range of insurance options, including vehicle insurance and comprehensive coverage services. SunCar will also provide automotive services through its nationwide network and assist Lotus in promoting its vehicles across various regions.

07:42 EDT OptimizeRx delivers AI-guided privacy-compliant platform - OptimizeRx announced its continued commitment to partnering with pharmaceutical brands to navigate the rapidly changing landscape of state-level consumer privacy legislation while executing comprehensive marketing programs nationwide. This month Florida, Oregon, and Texas, representing just over 16% of the nation's population, joined California, Colorado, Connecticut, Delaware, Maine, Michigan, Minnesota, Nevada, New York, Utah, Vermont, Virginia and Washington with existing consumer privacy laws. The changing landscape and state-by-state approach makes it particularly difficult for organizations to manage compliance with healthcare marketing in the US, and to create a unified engagement approach. OptimizeRx is offering expertise, patented technology, and solutions that enable pharmaceutical brands to reach their target audiences effectively and in compliance with privacy regulations.

07:39 EDT Mogo teams with investment strategist Tom Lee & Fundstrat for its clients - Mogo announced a new partnership with Thomas Lee and FS Insight or FSI to provide members of the company's digital wealth platform, Mogo and Moka, with exclusive access to research and related products and services produced by FSI - a market-leading, independent research firm within Fundstrat Global Advisors . Fundstrat/FSI was co-founded by Mr. Lee who is a top-ranked Wall Street analyst with more than 30 years of research experience, the former Chief Equity Strategist at global investment bank JPMorgan, and a contributing editor with CNBC; and John Bai, former Wall Street sales executive. FSI provides individuals with the same quality of research that banks and hedge funds receive to make their investment decisions....Under the agreement, Mogo will be the exclusive distributor of FSI's research to Canada's retail investor market. In addition to a broad array of subscription-based research, Mogo and Moka users will have access to exclusive interviews and webinars produced by FSI, as well as appearances featuring Tom Lee and Mark Newton, Head of Technical Strategy at FSI. FSI research will be available to Mogo members beginning this quarter.

07:37 EDT GE Aerospace CEO says new engine output 'disappointing' - Says 80% of material shortages attributable to 15 supplier sites.

07:36 EDT BridgeBio appoints Trimarchi as President, COO - BridgeBio Pharma announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer, COO, of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized operation across the late-stage pipeline prioritizing efficiency, rigor, and scale.

07:35 EDT DraftKings plans to launch mobile sports betting in Washington D.C. - DraftKings announced its intention to launch its top-rated online sportsbook in Washington D.C., pending licensure and regulatory approvals. The expected arrival into the nation's capital follows a market access agreement with D.C. United, which would pave the way for the digital sports entertainment and gaming company to operate in The District of Columbia. "It has been incredible to see legalized sports betting grow rapidly over the past six years, and with plans to launch our online sportsbook in D.C., DraftKings looks forward to expanding its presence in more than half the country," said Matt Kalish, President, DraftKings North America. "We would like to thank the D.C. Council for creating a path to bring DraftKings' top-rated sportsbook to the nation's capital. Together with D.C. United, we look forward to delivering fans a best-in-class experience through our customer-friendly product."

07:33 EDT Lockheed Martin reports Q2 cash from operations of $1.9B; free cash flow $1.5B

07:32 EDT Lockheed Martin backs FY24 cash from operations view $7.75B-$8.05B - Backs FY24 free cash flow view $6B-6.3B; CapEx ~$1.75B.

07:21 EDT BeiGene opens facility in New Jersey - BeiGene announced the opening of its flagship U.S. facility in Hopewell, New Jersey, at the Princeton West Innovation Campus, which houses biologics manufacturing capabilities and a clinical research and development center that further bolster the company's differentiated model as an oncology innovator. BeiGene has more than 30 molecules at clinical or commercial stage, and the 42-acre facility provides flexibility to scale production of its innovative medicines in the future to meet the needs of patients with cancer.

07:19 EDT Aeva Technologies technology selected by national defense security organization - Aeva announced that a national defense security organization has chosen Aeva's 4D LiDAR technology to help protect energy infrastructure sites across the United States. Aeva's sensors are expected to be the primary detection sensor to protect sensitive locations in various facilities from intrusion, such as water entries and exits and at perimeter fences, with first deliveries expected later this year.

07:15 EDT Gilat awarded over $9M for its GEO, NGSO satellite communications solutions - Gilat Satellite Networks announced that the Company was awarded over $9M in cumulative orders from multiple satellite operators to expand their global SATCOM networks utilizing Gilat's innovative and field-proven solutions. Gilat's solutions will be used to enable a wide range of services and applications over GEO and NGSO, including in-flight connectivity, maritime mobility, cellular backhaul, and enterprise services and more. "These orders reinforce our position at the forefront of the new space era industry, as satellite operators rely more and more on Gilat to meet the complex demands of multi-orbit operation," said Hagay Katz, Chief Product and Marketing Officer at Gilat. "This achievement underscores our commitment to innovation and reliability, enabling us to deliver cutting-edge solutions that address the massive growth and evolving challenges of the satellite communications industry."

07:13 EDT uniQure announces closing of sale of manufacturing facility to Genezen - uniQure announced the closing of the sale of its global manufacturing facility in Lexington, Massachusetts to Genezen, a leading contract development and manufacturing organization specializing in the supply of retroviral vectors, lentiviral vectors, and adeno-associated virus, AAV technologies. uniQure and Genezen expect a seamless transition, with nearly all employees who were offered employment successfully joining Genezen. As a result of the transaction, uniQure becomes a meaningful shareholder of Genezen and Mr. Kapusta has joined Genezen's Board of Directors. uniQure expects immediate reductions in future recurring cash burn of approximately $40 million per year, which includes interest expense savings from the retirement of $50 million in outstanding debt. With the transaction now complete, Amin Abujoub, Ph.D. who currently serves as Chief Quality Officer has been appointed to the new role of Chief Technical Operations Officer. As a result of the divestiture, the Chief Operating Officer role was eliminated, and Pierre Caloz will depart the company, continuing to lend his expertise in an advisory capacity.

07:12 EDT Singing Machine launches official TikTok shop - The Singing Machine Company announces it has entered into a formal partnership with TikTok Shop pursuant to which The Singing Machine is now officially designated as a TikTok Shop Seller. With this new status, the Company expanded its online reach to over 150 million daily users on TikTok, one of the largest and fastest growing retail channels available to consumers today. The launching of the Singing Machine TikTok Shop underscores a shared commitment to enriching the livestream shopping experience for karaoke products on the TikTok platform.

07:09 EDT Eyenovia, Senju sign collaboration agreement - Eyenovia announced that it has entered into a collaboration agreement with Senju Pharmaceutical, under which both companies intend to work to develop Senju's corneal epithelial wound healing candidate, SJP-0035, for use with Eyenovia's Optejet dispensing technology, as a potential treatment for chronic dry eye disease. Per the terms of the agreement, Eyenovia and Senju are planning to meet with the U.S. Food and Drug Administration, FDA, to present a clinical development proposal that, if successful, could support a New Drug Application, NDA, filing for a novel drug-device combination product for the treatment of chronic dry eye disease. SJP-0035 as an eye drop has been shown in prior Phase 1 and Phase 2 studies to be well tolerated at multiple doses tested in over 250 subjects. A planned Phase 2b trial would evaluate SJP-0035 administered in the Optejet dispenser.

07:09 EDT Altair Engineering partners with UK university in aerospace digital twin project - Altair has signed a memorandum of understanding with the U.K.-based University of Nottingham for a digital twin project within the aerospace sector. The digital twin-set aims to be not merely a technology demonstrator, but a fully-fledged solution the industry can use to design, validate, and test the electric propulsion systems of new aircraft or advanced air mobility vehicles and/or to evaluate the retrofit of existing ones. The agreement will give University of Nottingham researchers unlimited access to the Altair HyperWorks design and simulation and Altair RapidMiner data analytics and artificial intelligence platforms.

07:07 EDT Ero Copper achieves first saleable copper concetrate production - Ero Copper announced a significant commissioning milestone at the Tucuma Project with the production of saleable copper concentrate, which exceeded process design concentrate grade targets. This milestone was achieved following the successful commissioning of the milling and flotation operations prior to the end of Q2 2024. Remaining work on site is focused on concluding non-critical path surface installations and ramping up to commercial production. 2024 commissioning milestones: Completion and commissioning of primary, secondary, tertiary crushers, screening and conveyance systems - March 2024; Completion of mine pre-strip and commencement of full mine operations - April 2024; First ore through the milling and flotation circuits - mid-June 2024; First batch of copper concentrate production - June 24, 2024; Completion of first 24-hour shift of continuous mill operations - July 7, 2024; First saleable copper concentrate production, which exceeded process design concentrate grade targets - July 18, 2024; Expect to reach commercial production levels, defined as 80% of design mill capacity and 80% of design recovery rates, by the end of Q3 2024. "Producing our first saleable copper concentrate at the Tucuma Project and successfully completing the first 24-hour shift of continuous mining and milling operations are important milestones as we begin our ramp-up towards commercial production," said David Strang, Chief Executive Officer. "We are rapidly progressing towards an important inflection point for our consolidated copper production and cash flows. It is an exciting time for the Company and with copper prices performing well year-to-date, the timing of the completion and ramp-up of Tucuma could not be better."

07:04 EDT Dream Chasers to nominate two directors to Carver Bancorp board - Dream Chasers Capital said, "Dream Chasers Capital believes it's time to Make Carver Great Again. In that endeavor, Dream Chasers Capital Group - Carver Bancorp's largest minority shareholder with a 5% stake - is nominating 2 new members to the bank's board at its upcoming annual shareholder meeting and we are asking for your vote. On July 12, 2024, DCCG sent Carver's board a slate of 2 new nominees for election to the board at the bank's upcoming annual meeting. On July 18, 2024 Carver notified Dream Chasers of its receipt of our director nominees. The fund believes both nominees are not only supremely qualified, but if successfully elected by you the shareholders, will execute a new strategic plan for growth which will lead to profitability, enrich the community and deliver significant shareholder value. We are confident that fellow Carver shareholders will view these 2 nominees as aligned with their interests and we see no reason why the bank should have any issues with these exceptional directors. We believe any attempt to deny these directors a vote - out of self-preservation or self-interest - may be a catalyst for an eventual sub $1 per share stock price, significantly handicap the bank's ability to raise future capital to carry out its mission and present going concern risk. Dream Chasers believes it has the tacit support of a large percentage of Craver's shareholders and we remain open to negotiation for the benefit of all shareholders. We encourage the Board to do the right thing as shareholder watch. About nominee #1: Jeff Anderson: Mr. Anderson is 63 yr. old and a recently retired financial executive with J.P. Morgan where he previously served in a CFO role that oversaw 850 tri-state area banking centers and at the time comprised of an income statement with $3.7 billion in revenue, $1.7 billion in pretax earnings as well as a balance sheet of $100 billion in deposits and investments, and $15 billion in loans...About Nominee #2: Jeffrey John Bailey: Mr. Bailey is Carver's largest individual shareholder and owns between approximately 5 to 8% of the bank's equity. Mr. Bailey is a serial entrepreneur, who over the last 30 years, has founded and successfully implemented business plans, strategies and hired teams to execute such plans resulting in millions of dollars in revenues and profits and delivering investor returns. Mr. Bailey shares a lifelong passion in wanting to see communities of color do better and has supported such endeavors over the years with capital and action. In conclusion, the time for new blood, new energy and new ideas is now. You the shareholders, you the real owners of the bank, you, some of whose investments are down 80%, get to decide. No longer can shareholders afford to sit idle and have a board, who own very little of the company shares, continue to - out of self-preservation, status quo and cronyism - resist positive changes while offering no good ideas to deliver shareholder value. It is your hard-earned money at stake. We encourage shareholders - retail and institution - to show up and vote for our nominees at the bank's upcoming annual meeting."

06:52 EDT Asensus Surgical's Senhance Surgical System granted FDA clearance in urology - Asensus Surgical has received 510(k) clearance from the FDA for an expanded indication to treat adult and pediatric Urology patients with the Senhance Surgical System. While the Senhance System has been utilized for Urology procedures outside the U.S. for several years, this expanded indication will open the door to this specialty to leverage the advantages of the Senhance System in the U.S. patient population.

06:48 EDT Merck reports 'positive' results from Phase 2b/3 trial of clesrovimab - Merck announced positive topline results from its Phase 2b/3 clinical trial evaluating clesrovimab (MK-1654), the company's investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus disease. In the trial, clesrovimab met its primary safety and efficacy endpoints, including reducing medically attended lower respiratory infections caused by RSV through Day 150.

06:40 EDT ViiV Healthcare premier early data on INSTI VH184 - GSK (GSK) announced that ViiV Healthcare, a company majority owned by GSK, with Pfizer (PFE) and Shionogi as shareholders, shared positive in vitro findings showing that an investigational integrase strand transfer inhibitor, INSTI, VH4524184, VH184, retained its antiviral activity and could be effective in countering second-generation INSTI resistance. Additional analysis presented of a phase I study showed pharmacokinetic and safety data supported further development of VH184. The findings are being presented at the 25th International AIDS Conference being held in Munich, Germany, from 22 - 26 July 2024. The presentation at AIDS 2024 is a combination of two separate analyses. The first evaluated VH184, in vitro, against more than 20 clinically derived HIV-1 viruses with mutations known to be associated with resistance to INSTIs. These viruses were identified from two phase III clinical trials of second-generation integrase inhibitors in treatment-experienced people living with HIV. Results from this analysis suggest VH184 has a resistance profile distinct from prior generations of INSTIs, showing that it was able to retain antiviral activity against clinically relevant mutations.

06:34 EDT Owens & Minor to acquire Rotech Healthcare Holdings for $1.36B - Owens & Minor has entered into a definitive agreement to acquire Rotech Healthcare Holdings, a privately held home based care business headquartered in Orlando, Florida, for $1.36B in cash. Given anticipated tax benefits of approximately $40 million from the transaction, the net purchase price is approximately $1.32B, which represents approximately a 6.3x multiple of LTM EBITDA, excluding synergies. Rotech is a national provider of home medical equipment in the U.S. The company has over 4,200 employees and provides products and services in 46 states through approximately 325 operating locations. Rotech generated approximately $750M of revenue and an EBITDA margin of nearly 30% in 2023. The transaction is expected to be adjusted EPS neutral in the first full year and provide approximately 15c accretion in the second year, to strengthen patient direct product offerings through expansion across a complementary portfolio, support combined customer base, provide synergy opportunity of approximately $50M by the end of year three, with further upside potential, as well as prospect for additional revenue synergies in both the near and long term. Owens & Minor has fully committed financing in place and expects to use a combination of cash and incremental borrowings to fund the purchase price. The transaction is expected to close by the end of 2024.

06:28 EDT GE Aerospace sees FY24 adjusted tax rate in the low 20s - Sees FY24 interest expense slightly below $1B.

06:23 EDT ViiV Healthcare announced Dovato as effective as Biktarvy for HIV-1 - GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as shareholders, has shared 48-week findings from the PASO DOBLE study, the largest head-to-head, phase IV randomised clinical trial investigating the 2-drug regimen Dovato, DTG/3TC, compared to the 3-drug regimen Biktarvy, BIC/FTC/TAF, for the treatment of HIV-1 in people who are virologically suppressed and who could benefit from treatment optimisation. Findings showed that switching to DTG/3TC in virologically suppressed adults living with HIV demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to BIC/FTC/TAF. These data will be presented at the 25th International AIDS Conference, AIDS 2024, held in Munich, Germany. In the PASO DOBLE clinical trial, 553 people living with HIV and virally suppressed switched treatment to either DTG/3TC or BIC/FTC/TAF. The study met its primary endpoint when DTG/3TC demonstrated non-inferior efficacy versus BIC/FTC/TAF based on the proportion of participants with viral RNA greater than or equal to50 copies/mL at 48 weeks using the FDA snapshot and a 4% non-inferiority margin in the exposed intention-to-treat population. At 48 weeks, DTG/3TC was non-inferior to BIC/FTC/TAF. One participant in the BIC/FTC/TAF arm and zero in the DTG/3TC arm had protocol-defined confirmed virological failure through week 48. The study found in a key secondary endpoint that weight increased significantly more in participants who switched to BIC/FTC/TAF than in those who switched to DTG/3TC through week 48. Equally, the proportion of participants with weight gain greater than 5% at week 48 was significantly higher at 29.9% for BIC/FTC/TAF compared to 20% for DTG/3TC, DTG/3TC-treated individuals had significantly less weight gain compared to those randomised to BIC/FTC/TAF

06:13 EDT Atlas Energy and Kodiak partner in autonomous trucking technology - Atlas Energy and Kodiak Robotics have entered into an agreement whereby Kodiak will outfit new Atlas high-capacity trucks with Kodiak's autonomous driving technology. The two companies have already completed their first driverless delivery of frac sand in West Texas's Permian Basin. Atlas has placed an order for Kodiak-equipped driverless trucks that will deliver frac sand across the Permian Basin's existing infrastructure of private lease roads. Early next year, Atlas plans to launch commercial operations using its first two trucks equipped with the Kodiak Driver, Kodiak's industry-leading autonomous system. Kodiak will provide its technology to Atlas via a driver-as-a-service licensing agreement. Atlas will own the trucks, and Kodiak will provide the Kodiak Driver's fully-redundant, platform-agnostic, hardware and software stack.

06:07 EDT Radware expands cloud services - Radware announced it has expanded its cloud services to include a new Domain Name System as a Service and a solution for private key protection, storage, and management called NoKey. The two new solutions offer security-conscious organizations more flexibility and control over application delivery, security, and performance.

06:00 EDT Julius Baer names Goldman's Stefan Bollinger as CEO - Julius Baer (JBAXY) announced that, following a comprehensive search, the Board of Directors has appointed Stefan Bollinger as CEO. He will start his new role at Julius Baer no later than February 1, 2025. Bollinger is currently Co-Head Private Wealth Management for Europe, Middle East and Africa at Goldman Sachs (GS) in London. Reference Link

05:35 EDT Equinix acquires three data centers from TIM in Southeast Asia - Equinix announced its planned entry into the Philippines with the acquisition of three data centers from Total Information Management, or TIM, a technology solutions provider. Following the recently announced expansions in Malaysia and Indonesia, this strategic move aims to help businesses expand and capitalize on the digital opportunity of the Southeast Asia region. The all-cash transaction represents a multiple of approximately 15x the projected EBITDA at full utilization and is expected to close in 2H 2024, subject to customary closing conditions. The acquisition of the three high-performance data centers will provide capacity for Equinix to address the digital needs of local and overseas businesses in the Philippines.

05:30 EDT Lilium, SEA and Skyports Infrastructure sign MoU for eVTOL network in Italy - Lilium, SEA, the operator of Milan's airports, and Skyports Infrastructure, have announced the signing of a memorandum of understanding, or MoU, laying the groundwork for the development of a passenger electric vertical take-off and landing, or eVTOL, network in the Lombardy region in the north of Italy. The Lombardy region is a strategically important location for the partners. With the signing of the MoU, the parties will collaborate to launch a vertiport network with operators of the Lilium Jet as soon as 2027. SEA will contribute as majority shareholder, providing airport management capability and deep knowledge of the region's aviation and infrastructure ecosystem. Skyports will provide its expertise and experience in the development and integration of vertiport infrastructure, working closely with SEA on the operation of the vertiports. Lilium brings aircraft expertise and its pioneering Lilium Jet, designed to offer capacity, the longest operational range at the highest speed, with minimal noise, while maintaining zero operating emissions. The agreement will see the parties develop regional air mobility routes that serve key locations across Lombardy. The first route to be developed will connect Milan Malpensa Airport - the largest international airport in northern Italy, which transported over 26M travelers last year - and Milan city centre. The project formalized by the MoU will allow for the establishment of a network of routes for the operation of the Lilium Jet and other eVTOL aircraft, enhancing accessibility and connectivity for regional air mobility. For the development and operations of vertiports in Lombardy and Italy, SEA, Skyports and their shareholder 2i Aeroporti are in the process of establishing a joint venture company.

05:24 EDT Constellium signs long-term agreement with Lotte Infracell - Constellium announced that it has signed a long-term agreement with Lotte Infracell, a subsidary of Lotte Aluminium, a provider of aluminum solutions, to supply foilstock for Lotte's battery foil applications in Europe. This partnership highlights Constellium's commitment to the growing electric vehicle market and its strategic focus on cutting-edge automotive aluminum solutions. Under this agreement, Constellium will supply high-quality foilstock from its Singen site in Germany. With Lotte Infracell's financial support, Constellium is planning to invest around EUR 30M in new finishing lines at its Singen facility to enhance production capacity, creating around 20 new jobs in the process. This strategic investment is expected to further cement Constellium Singen's position as a key player in the aluminum automotive specialties market.

05:20 EDT dMY Technology II gets FDA feedback for accelerated approval pathway for Diamyd - Diamyd Medical received feedback from the FDA regarding an accelerated approval pathway for its immunotherapy, Diamyd, for treating patients with Stage 3 Type 1 Diabetes carrying the genotype HLA DR3-DQ2. In a recent in-person Type C Meeting, the FDA acknowledged that C-peptide could be used by Diamyd Medical as a surrogate endpoint reasonably likely to predict the clinical benefit of preservation of endogenous insulin production. As such, accelerated approval could be sought based on a demonstration of significant treatment-related benefits on C-peptide levels in response to Diamyd administration. Diamyd Medical has and will continue to have ongoing discussions with the FDA to determine the requirements for a biologics license application, or BLA, under an accelerated approval pathway, including a potential earlier readout of stimulated C-peptide from the ongoing Phase 3 trial DIAGNODE-3.

05:13 EDT Cognizant, Whitbread expand relationship - Cognizant and Whitbread have expanded their digital transformation relationship which will see the professional services provider support the hospitality company's ongoing digital transformation with product design, product management and engineering as Whitbread expands its operations in the UK and Germany. The renewed relationship will focus on realising Whitbread's digital growth strategy which looks to deliver an enhanced customer experience.

05:06 EDT MAIA Biotechnology provides update on THIO-101 trial - MAIA Biotechnology announced treatment updates from its Phase 2 clinical trial, THIO-101, evaluating THIO sequenced with the immune checkpoint inhibitor, or CPI, cemiplimab in patients with advanced non-small cell lung cancer, or NSCLC, who failed two or more standard-of-care therapy regimens. The trial's therapeutic regimen is cycled every three weeks, with THIO 180mg administered in 60mg incremental doses on days 1, 2 and 3, followed by immune activation on day 4, and cemiplimab 350mg administered on day 5. As of the latest clinical cutoff date, June 12: six patients remain on treatment following at least 12 months of therapy. Treatment with THIO followed by cemiplimab has been well tolerated throughout the trial, with much lower toxicity compared to standard-of care treatments. Continuing treatment past 12 months demonstrates safety, efficacy and ongoing benefit from MAIA's novel telomere targeting NSCLC therapy.